Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 3, 2011, Pages 263-269

  Middelkoop, Keren ^a   Bekker, Linda Gail ^a   Myer, Landon ^a,b   Johnson, Leigh F ^a   Kloos, Matthew ^c   Morrow, Carl ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Columbia University ^*  (United States)

^c NONE

Author keywords

antiretroviral; community; HIV; notification rates; tuberculosis

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMMUNITY; DISEASE ASSOCIATION; FATALITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOUTH AFRICA; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE NOTIFICATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREVALENCE; SOUTH AFRICA; TUBERCULOSIS;

EID: 79951805147     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820413b3     Document Type: Article

References (31)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Available at: http://www.who.int/tb/publications/ global-report/ 2009/en/index.html. 2009. Accessed August 3, 2010.
2. World Health Organization. WHO three I's meeting: intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Available at: http://www.who.int/hiv/pub/ meetingreports/WHO-3Is-meeting-report.pdf. 2008. Accessed August 3, 2010.
3. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002; 359:2059-2064. (Pubitemid 34680968)
4. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19:2109-2116. (Pubitemid 41668999)
5. World Health Organisation: The Global Plan to Stop TB, 2006-2015 Stop TB Partnership. Geneva, Switzerland: WHO; 2006. Available at: http:// www.stoptb.org/globalplan/plan-p2main.asp?p=2http://www.stoptb.org/ globalplan/plan-p2main.asp?p=2. Accessed August 3, 2010.
6. World Health Organisation.Treating 3 million people by 2005: Making it Happen. The WHO Strategy. Available at: http://www.who.int/3by5/ publications/documents/en/3by5StrategyMakingItHappen.pdf. 2003. Accessed August 6, 2010.
7. The United States President's Emergency Plan For AIDS Relief: Fact Sheet. Available at: http://www.pepfar.gov/documents/organization/115411.pdf. 2009. Accessed August 6, 2010.
8. The global fund to fight AIDS, tuberculosis and malaria: annual report. 2008;Available at: http://www.theglobalfund.org/documents/publications/ annualreports/2008/AnnualReport2008.pdf. Accessed August 6, 2010.
9. World Health Organisation, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Available at: http://www.who.int/hiv/pub/towards-universal-access- report-2008.pdf. 2008. Accessed August 6, 2010.
10. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148. (Pubitemid 41669003)
11. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006; 20:1605-1612. (Pubitemid 44162402)
12. Girardi E, Sabin CA, d'Arminio MA, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005;41:1772-1782. (Pubitemid 41759864)
13. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science. 2003;301:1535-1537. (Pubitemid 37128545)
14. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med. 2007;175:87-93. (Pubitemid 46105314)
15. South African Department of Health. The South African Tuberculosis Control Programme. Practical Guidelines. Pretoria, South Africa; South African Department of Health 2004.Available at: http://www.capegateway. gov.za/Text/2003/tb-guidelines2000.pdf. Accessed July 27 2010.
16. Health Systems Trust. Cape Town TB Control. Progress report 1997- .2003. Available at: www.hst.org.za./publications/618. 2004.
17. Lawn SD, Bekker LG, Middelkoop K, et al. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis. 2006;42: 1040-1047.
18. Johnson LF, Dorrington RE. Modelling the demographic impact of HIV/AIDS in South Africa and the likely impact of interventions. Demographic Research. 2006;14:541-574. (Pubitemid 43994815)
19. Actuarial Society of South Africa. ASSA2003 AIDS and demographic model. Available at: http://aids.actuarialsociety.org.za/ASSA2003-Model- 3165.htm. 2005. Accessed July 15, 2010.
20. Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med. 2010; 182:1080-5. (E-pub ahead of publication).
21. Cochran WG. Some methods for strengthening the common X2 test. Biometrics. 1954;10:417-451.
22. De Cock KM, Soro B, Coulibaly IM, et al. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA. 1992;268:1581-1587.
23. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis. 2007;13:1001-1007. (Pubitemid 47048071)
24. Varma JK, Nateniyom S, Akksilp S, et al. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis. 2009;9:42.
25. Grant AD, Djomand G, De Cock KM. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS. 1997;(11 suppl B): S43-S54.
26. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42: 464-469. (Pubitemid 44050895)
27. South African Department of Health. National antiretroviral treatment guidelines. Available at: http://www.hst.org.za/uploads/files/sa-ART- Guidelines1.pdf. 2004. Accessed August 11, 2010.
28. Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23:1717-1725.
29. Lawn SD, Wilkinson RJ, Lipman MC, et al. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med. 2008;177:680-685. (Pubitemid 351490554)
30. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet. 2006;368:1254-1259. (Pubitemid 44508698)
31. Zeinecker J, Morrow C, van Soelen N, et al. Missing the target despite high population levels of anti-retroviral therapy coverage in a South African community. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Capte Town; July 20 2009; MOPED031. Available at: http://www.ias2009.org/ mainpage.aspx?pageId=334. Accessed August 11, 2010.